Services
Ebooks
Navigating Intensifying Cell Therapy Regulatory Expectations
In our new eBook, Navigating Intensifying Cell Therapy Regulatory Expectations, Kincell Bio’s scientific and executive leadership break down what’s changed, why programs...
Defining Identity, Potency, and Quality with Confidence
Characterization and release testing form the backbone of a reliable cell therapy control strategy. Kincell Bio designs phase-appropriate testing frameworks that define identity, potency, purity, and safety while deepening product understanding. By linking assays to critical quality attributes, we support IND readiness, comparability planning, and scalable, inspection-ready commercial manufacturing.
Overcoming Characterization Complexity with Integrated, Phase-Appropriate Strategies
Cell therapy characterization is challenged by donor variability, complex cellular phenotypes, potency, and limited early clinical material. Weak assay robustness or poorly defined CQAs can lead to inconsistent data and regulatory risk. Kincell Bio addresses this by integrating analytical and process development, enabling characterization strategies to mature alongside development and support reliable, regulatory-ready outcomes. Key elements of our approach include:
Aligning identity, potency, purity, and safety assays to critical quality attributes (CQAs) and intended clinical use.
Deploying standardized platform methods, such as flow cytometry panels, then customizing assays with program-specific markers and potency readouts to balance efficiency, comparability, and scientific precision.
Combining flow cytometry, functional potency, and molecular approaches to strengthen confidence in characterization data.
Building phase-appropriate controls and documentation, then progressing to qualification and validation for release-critical methods.
Generating consistent, traceable datasets that support process changes, scale-up, and regulatory expectations.
Characterization & Release Testing Strategies Tailored for Autologous and Allogeneic Cell Therapies
Effective characterization and release strategies must reflect the distinct variability, scale, and regulatory demands of autologous and allogeneic cell therapies.
Autologous Cell Therapies
For autologous cell therapies, we design characterization and release strategies that account for patient-to-patient variability while safeguarding the chain of identity. Robust flow cytometry, functional potency assays, sterility testing, and molecular analytics ensure each individualized batch meets defined safety, purity, and performance criteria.
Allogeneic Cell Therapies
Kincell implements characterization and release strategies for allogeneic cell therapies, with a focus on batch consistency, scalability, and comparability. Comprehensive potency, genetic modification, purity, and in-process testing are combined with data trending and tightened specifications to ensure uniform performance across large-scale production and diverse patient populations.
Characterization & Release Testing
Capabilities At-a-Glance
Kincell Bio facilities are well-equipped with a range of platform technologies, enabling robust characterization and release testing solutions, increasing program success, and derisking your development journey.
Characterization Assays
Cell phenotype
- Cell health
- Immune-phenotyping
- Apoptosis
- T-cell subset assessment
Potency
- Cytotoxicity by impedance
- Flow cytometry
Secretome assessment
- Cytokine assessment
Release Testing Performed
- Sterility
- Mycoplasma
- Endotoxin
- Surrogate VSV-G via PCR
- Vector copy number
- Appearance
- pH
- Presence of transgene (VCN)
- Immuno-phenotyping
- Residual beads
- IFN-gamma release
- Viability/cell count
Bringing Cell Therapy Discoveries to Life
Kincell Bio develops and delivers tomorrow’s cell therapy cures by integrating comprehensive, end-to-end capabilities across the full product lifecycle, with deep expertise spanning a broad range of autologous and allogeneic cell therapy modalities.
Integrated Services
Articles
The Regulatory Bar for Cell Therapies Has Been Raised – Are You Ready?
Since 2024, four different cell and gene therapy programs have hit the same wall: manufacturing readiness. Capricor’s CAP-1002 (allogeneic cell therapy for...
Webinars
Delivering Cell Therapies for Patients
Watch our capabilities presentation to learn how our integrated CDMO solutions accelerate immune cell therapy development from early-phase to commercial readiness.
Talk to an expert
Turning Cell Therapy Innovation Into Patient Impact
Leveraging our science-first expertise and right-first-time quality, partner with Kincell Bio to advance your cell therapy from concept to commercialization.
"*" indicates required fields